Navigation Links
AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
Date:9/5/2012

IRVINE, Calif., Sept. 5, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, will be a presenting company at the Rodman & Renshaw 14th Annual Healthcare and Global Investment Conference to be held in New York City from September 9 -11, 2012 at the Waldorf-Astoria.  Mark Selawski, CFO of AtheroNova, will present at 3:15pm ET on Tuesday, September 11.

Mr. Selawski will discuss exciting near term milestones for AHRO-001, the Company's lead compound for the regression of atherosclerotic plaque, as well as the Company's pipeline and development plans. 

In addition to the presentation, Mr. Selawski will be available to meet with analysts, industry executives and investors in one-on-one meetings.  Those interested in meeting with Mr. Selawski for a one-on-one discussion during the Conference are encouraged to contact the Company directly at info@atheronova.com.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits.  The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding the Company's pipeline, milestones and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. AtheroNova Releases 2011 Financial Results
2. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
3. AtheroNova Announces a New Board Member
4. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
5. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
6. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
7. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
8. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
9. Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
10. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
11. Life Technologies to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... NDA Partners Chairman ... Director of Product Development R&D at Allergan and CMC expert with more than ... and established biopharma companies, has joined the firm as an Expert Consultant. ...
(Date:6/26/2017)... RESTON, Va (PRWEB) , ... June 26, 2017 , ... ... on the use of health IT to create efficiencies in healthcare information exchange and ... announced Donald W. Rucker, MD, head of the federal Office of the National Coordinator ...
(Date:6/23/2017)... ... 23, 2017 , ... Biova, LLC., the leader in water soluble egg membrane ... Dr. Henig will bring a wealth of scientific experience in the food, beverage, nutrition ... and Scientific Officer of four major global companies in the last 4 decades. ...
(Date:6/23/2017)... UK (PRWEB) , ... June 23, 2017 , ... Ken ... Lula, president of Physik Instrumente USA, have been selected as this year’s recipients of ... , The two have been invited along with other honorees to accept their awards ...
Breaking Biology Technology:
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):